Northwest Biotherapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Northwest Biotherapeutics's past years’ income statements indicate that its last revenue has increased compared to the previous period by 15% to $1,932,000. The net income raised on -$62,599,000 and profit margin reached -3240%. Total operating expenses were $57,440,000.
Profit Margin
| 2014 | 1.45M | -135.63M | -9328.34% |
|---|---|---|---|
| 2015 | 1.73M | -114.74M | -6598.1% |
| 2016 | 623K | -80.21M | -12875.44% |
| 2017 | 336K | -73.14M | -21768.75% |
| 2018 | 412K | -35.79M | -8687.86% |
| 2019 | 2.41M | -23.57M | -978.09% |
| 2020 | 1.29M | -538.36M | -41701.39% |
| 2021 | 1.00M | 179.12M | 17823.48% |
| 2022 | 1.68M | -136.84M | -8131.19% |
| 2023 | 1.93M | -62.59M | -3240.11% |
NWBO Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 1.93M | 1.68M | 1.00M | 1.29M | 2.41M | 412K | 336K | 623K | 1.73M | 1.45M |
Cost of revenue | 27.73M | 1.54M | 20.30M | 33.63M | 14.10M | 18.15M | 33.51M | 60.08M | 103.12M | 85.63M |
Gross profit | -25.79M | 135K | -19.30M | -32.34M | -11.69M | -17.74M | -33.17M | -59.45M | -101.38M | -84.18M |
Operating exp. | ||||||||||
Research and development | 27.73M | 35.51M | 20.30M | 33.63M | 13.59M | 18.15M | 33.51M | 60.08M | 103.12M | 85.63M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 57.44M | 68.86M | 53.70M | 87.89M | 29.87M | 45.16M | 55.01M | 79.88M | 128.02M | 102.59M |
Operating income | -55.50M | -67.18M | -52.70M | -86.60M | -27.46M | -41.48M | -54.67M | -79.26M | -126.28M | -101.14M |
Other income (expenses), net | -7.09M | -37.85M | 231.82M | -443.21M | 7.16M | 18.83M | -18.46M | 2.87M | 11.54M | -34.49M |
Income before tax | -62.59M | -105.03M | 179.12M | -529.82M | -20.29M | -35.79M | -73.14M | -80.21M | -114.74M | -135.63M |
Income tax expense | 0 | 31.81M | 4.36M | 8.54M | 3.27M | 15.55M | 3.24M | -1.86M | 4.15M | -17.90M |
Net income | -62.59M | -136.84M | 179.12M | -538.36M | -23.57M | -35.79M | -73.14M | -80.21M | -114.74M | -135.63M |
Earnings per share | ||||||||||
Basic EPS | -0.05 | -0.13 | 0.21 | -0.74 | -0.04 | -0.08 | -0.3 | -0.72 | -1.48 | -2.29 |
Diluted EPS | -0.05 | -0.13 | -0.05 | -0.74 | -0.04 | -0.08 | -0.3 | -0.72 | -1.48 | -2.29 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |